BMJ Open

Development and evaluation of a psychosocial adaptation questionnaire for women with breast cancer treated with adjuvant endocrine therapy: a single-centre, cross-sectional study in China

Haoran Jiang, Xiujie Zhang, Yu Dong, Hui Xu, Feng Jin

ABSTRACT

Objective To develop and evaluate a psychosocial adaptation (PSA) questionnaire of women with breast cancer treated with adjuvant endocrine therapy (AET).

Design Cross-sectional study.

Setting Conducted study in a tertiary care centre in China from March to June 2021.

Participants Women with breast cancer who have received AET.

Methods Item development and extraction were based on literature, qualitative interviews (n=16) and assessment of content validity. 300 participants were recruited to perform item analysis, internal consistency reliability and exploratory factor analysis by cross-sectional studies. Finally, test–retest, criterion validity and conformational factor analysis of the questionnaire were performed with 96 respondents.

Results An initial questionnaire was devised. The exploratory factor analysis demonstrated four factors: emotional response (six items), self-worth (five items), physical impacts (three items) and social communication (two items). The cumulative contribution of the factors was 65.057%. Cronbach’s alpha coefficient of the questionnaire was 0.876. The correlation coefficient between the questionnaire and General Self-Efficacy Scale was 0.565 (p<0.01). A 16-item questionnaire and its factorial structure were confirmed.

Conclusions The 16-item questionnaire had good reliability and validity. This could be a useful tool to assess the PSA levels among women with breast cancer treated with AET and provide a basis for further research.

INTRODUCTION

Breast cancer (BC) is the most diagnosed cancer globally, with 2.3 million new cases in 2020, accounting for 11.7% of all cancer cases in that year. BC accounts for one in four cancer cases and one in six cancer deaths among women. Approximately two-thirds of women with BC test positive for the oestrogen receptor (ER) and/or progesterone receptor (PR). Due to early diagnosis and aggressive adjuvant therapy, the 5-year survival rate for breast cancer is more than 91.2%, which is higher than that for other cancers. Updated clinical practice guidelines recommend extending the use of adjuvant endocrine therapy (AET) from 5 to 10 years.

Breast cancer has gradually become a chronic disease with higher survival rates. Breast cancer survivors (BCS) need to co-exist with cancer for a long time and learn to adapt to the disease. While physical functioning in quality of life improves over time after completion of aggressive cancer treatment, emotional and social functioning as well as some breast cancer-specific symptoms significantly worsen, with all symptoms of distress (except pain) being higher in breast cancer patients than in the general population. Compared with the general population, after AET, BCS experience physical symptoms and emotional issues as they enter remission.

Long period of AET brings immense pain to the patient’s body and mind. They often worry about disease recurrence and metastasis, and...
most have experienced hot flashes, night sweats, insomnia, stiff joints, weight gain, anxiety, depression, and a series of side effects. In addition, BCS also suffer from a variety of psycho-social distress due to self-blame (negative perceptions of cancer) and social stigma. Adaptation on a multi-dimensional level, such as social and sexual, while tolerating the symptoms of diagnosis and treatment is called psycho-social adaptation. Based on the perspective of positive psychology, PSA refers to the transition process of the person with disability from a state of disability to an enabling state, which is characterised by the transition from negative to positive happiness. PSA has both relation and difference with self-efficacy and health-related quality of life. BCS with an optimistic disposition, and with a positive perception of illness have better health-related quality of life. Self-efficacy is important for better PSA. Based on previous theories and studies, when women have BC treated with AET, they will adopt either a positive or negative attitude and behaviour to face it, which results in the changes of emotional dimension, self-cognition, self-image and social dimension. After an extensive literature review, no effective questionnaire was found that revealed the PSA of women with BC undergoing AET among the few studies available regarding the psychosocial adjustment of patients with BC. For instance, the Self-Reported version of the Psycho-social Adjustment to Illness Scale (PAIS-SR) was designed by Derogatis in 1986 to measure psychosocial adjustment in Greek patients with BC with heterogeneous cancer, and their close family members, with Cronbach’s alpha coefficients >0.620. When we used the Chinese version of the PAIS-SR to measure the PSA of women with BC treated with AET, patients felt that many contents of the questionnaire were not applicable, and the internal consistency coefficient was only 0.129. Therefore, shorter questionnaires needed to be devised, which can be quickly answered and easily managed in busy clinical centres.

To measure the PSA of patients with BC more accurately and provide better targeted intervention measures, our team constructed a questionnaire that evaluated PSA levels among BC women who have received AET, tested the questionnaire and subscales on women with BC treated with AET, and examined the reliability and validity of the new assessment tool.

**Table 1** Sociodemographic and clinical characteristics of the participants (n=396)

| Characteristics             | n (%)/mean±SD         |
|-----------------------------|-----------------------|
| Age(year)                   | 50.62±9.024           |
| BMI                         | 24.11±2.903           |
| Education level             |                       |
| Junior high school or below | 108 (27.272)          |
| High school/college         | 190 (47.980)          |
| Undergraduate college or above | 98 (24.748)       |
| Marital status              |                       |
| Married                     | 339 (85.606)          |
| Unmarried                   | 9 (2.273)             |
| Divorced                    | 31 (7.828)            |
| Widowed                     | 17 (4.293)            |
| Professional                |                       |
| Retired                     | 166 (41.920)          |
| Did not work                | 99 (25.000)           |
| Temporary worked            | 13 (3.283)            |
| Work as usual               | 118 (29.798)          |
| Years taking endocrine medications | 3.33±2.152 |

**METHODS**

Based on this preliminary concept, the development of the questionnaire included item development, questionnaire development and evaluation. This mixed research was conducted from March to June 2021 in China. Recruitment information was posted through the WeChat follow-up group of women with BC treated with AET at the Affiliated Hospital of China Medical University. According to the inclusion and exclusion criteria, participants were recruited online and voluntarily included.

Exclusion criteria were as follows: diagnosed with BC, positive ER and/or PR, received AET, women over the age of 18 years having BC and volunteering to participate in the study.

Exclusion criteria were as follows: women with other critical diseases (such as, severe infection, malignant tumours, malignant hypertension, myocardial infarction, severe cerebrovascular accident and heart failure).

**Item development**

The related literature on PSA levels in women with BC treated with AET was reviewed. This qualitative study was conducted through interviews and participatory observation. The literature reviewed and the information obtained from the participants (n=16) provided abundant data for the development of the item pool and the initial questionnaire. The PSA of women with BC treated with AET was closely related to emotional response, self-cognition, self-image and social situation.

**Questionnaire development**

Five experts (two BC specialists, two psychologists and one nursing specialist) assessed the questionnaire’s...
Table 2  Results of reliability and validity analysis for the PSA questionnaire among BC women with AET

| Factor | Item                                                        | Factor loading | Explanatory variation (%) | Cumulative explanatory variation (%) | Cronbach’s alpha coefficient | Correlation coefficient |
|--------|-------------------------------------------------------------|----------------|---------------------------|--------------------------------------|-----------------------------|-------------------------|
| 1      | Q1. I am worried about metastasis or recurrence            | 0.845          | 5.920                     | 36.997                               | 0.899                       | 0.857*                  |
|        | Q2. Breast problems make me feel nervous                   | 0.802          |                           |                                      |                             |                         |
|        | Q3. I am worried that breast disease will get worse        | 0.800          |                           |                                      |                             |                         |
|        | Q4. Breast problems make me feel scared                    | 0.795          |                           |                                      |                             |                         |
|        | Q5. I am worried about the side effects of the drug        | 0.705          |                           |                                      |                             |                         |
|        | Q6. Breast problems make me very depressed                 | 0.670          |                           |                                      |                             |                         |
| 2      | #Q7. I still think of myself as an attractive person       | 0.784          | 1.954                     | 12.211                               | 0.790                       | 0.685*                  |
|        | #Q8. Overall, I am satisfied with myself                   | 0.761          |                           |                                      |                             |                         |
|        | #Q9. I think I am still a valuable person                  | 0.738          |                           |                                      |                             |                         |
|        | #Q10. I can share happiness and sadness with friends and  | 0.660          |                           |                                      |                             |                         |
|        | colleagues                                                 |                |                           |                                      |                             |                         |
|        | #Q11. I am still interested in things I was interested in  | 0.649          |                           |                                      |                             |                         |
|        | before                                                    |                |                           |                                      |                             |                         |
| 3      | Q12. Breast problems affect my sex life                    | 0.795          | 1.468                     | 9.174                                | 0.664                       | 0.698*                  |
|        | Q13. I can not face the weight gain                        | 0.681          |                           |                                      |                             |                         |
|        | Q14. Disease affects my appearance and makes me unhappy   | 0.638          |                           |                                      |                             |                         |
| 4      | Q15. I am not willing to discuss breast problems with others | 0.861          | 1.068                     | 6.675                                | 0.730                       | 0.573*                  |
|        | Q16. I do not like others asking about my condition        | 0.839          |                           |                                      |                             |                         |

Confirmatory factor analysis.
*At level 0.01 (double tail), the correlation is significant. # is the reverse scoring item.
AET, adjuvant endocrine therapy; BC, breast cancer; PSA, psychosocial adaptation.
content validity through two rounds of panel discussions. In preparation for the formal survey, participants who met the criteria were chosen prior to the survey, and the difficulty, suitability and complexity of the items were assessed.

**Investigation**

There are two parts to the investigation. The sample size was determined by the item number, which met the requirement of 5–10 times the item number. In the first part, the initial questionnaire contained 56 items (56×5=280). A total of 300 participants (>280) were included to perform item analysis, internal consistency reliability and exploratory factor analysis (EFA). In the second part, the final questionnaire contained 16 items (16×5=80). Test–retest, criterion validity and confirmatory factor analysis (CFA) of the questionnaire were performed with 96 respondents (>80).

Sociodemographic characteristics of the participants were obtained in the survey, which included population-related and disease-related variables. The PSA questionnaire was developed for women with BC who have received AET. The answers were scored on a five-point Likert scale: all the time, often, sometimes, rarely and never. The higher the score, the better was the PSA level. The 10-item General Self-Efficacy Scale (GSES), developed by Schwarzer in 1981, has been widely used to measure self-efficacy and has been shown to have good reliability and validity.

The items were analysed using the critical ratio, discriminative index (DI) and item-total correlation (ITC). Items with values below the standard value were deleted. Construct validity was assessed using EFA and CFA. The internal consistency of the questionnaire was evaluated using Cronbach’s alpha coefficient. Test–retest reflects the stability and consistency of the test over time. After 10–18 days, 31 patients completed the questionnaire again, and the correlation coefficients of the two measures were used to assess the reliability of the retest. The Spearman correlation coefficient test was used to assess the validity of scale stability. The GSES was used to assess criterion validity.28

**Statistical analysis**

If an item was not answered, the score was replaced with the average. If two or more questions were not answered, the questionnaire was excluded from analysis. In the qualitative part, all data were managed and analysed using NVivo V.11.0. In the quantitative stage, IBM SPSS Statistics 25.0 and AMOS 23.0, were used for statistical analysis.

**Patient and public involvement**

No patient or public involvement.

**RESULTS**

**Participant characteristics**

A total of 409 women with BC treated with AET were selected between May and June 2021, of which 396 patients agreed to participate (response rate=96.82%). The sociodemographic and clinical characteristics of the study participants are presented in table 1.

**Development and analysis of items**

**Item pool**

The initial questionnaire included items related to the literature, qualitative research and group discussion.
Content validity was evaluated by five specialists (three breast specialists and two psychologists) through two rounds of panel discussions. The content validity index (CVI) of 76 questionnaires ranged from 0.769 to 0.893, and the average of the first round was 0.832. The content validity after deleting the 19 items was 0.930. A pre-experiment was conducted with 37 women with BC receiving AET to test the reliability of the questionnaire contents, of which 31 completed questionnaires were returned (recovery rate: 83.78%). Women with BC receiving AET judged the content of the questionnaire for appropriateness and accuracy. Cronbach’s alpha coefficient of the questionnaire was 0.934 (p<0.05).

**Item analysis**

After an independent sample t-test, item 2, which proved that the discrimination was poor, was deleted. Items with DI and ITC <0.3 were deleted at the same time. Consequently, a total of 17 items were deleted.

**Exploratory factor analysis**

Twenty-three items were deleted in 21 rounds of EFA. From the perspective of factor load and content, the first subscale was ‘emotional response’ consisting of six items. The second subscale was ‘self-worth’, which consisted of five items. The third subscale was ‘physical impacts’, consisting of three items, and the fourth subscale was ‘social communication’, consisting of two items (table 2, online supplemental file 1). The Kaiser-Meyer-Olkin (KMO) index of the 16-item questionnaire was 0.880, and the result of Bartlett’s spherical test was 2129.914 (p=0.000), which was suitable for factor analysis. When the eigenvalue was >1.0 (figure 1), four factors were extracted through principal factor analysis and varimax rotation, and the cumulative contribution rate of the factors was 65.057%.

CFA was used to further evaluate the construct validity, and the results are shown in figure 2. Except for Item 10, the load coefficient of the standardised factor obtained was >0.50. The path coefficients of the four subscales were highly correlated (p<0.001, table 3). The discrimination degree of the questionnaire and common fitting indices of the CFA model are listed in table 4, and the Pearson correlation coefficient between subscales is 0.165–0.760 (p<0.001).

**Table 3**  Confirmatory factor analysis of PSA in BC women with AET

| Items | Estimate | SE | Z | P value | Estimate | CR | AVE  |
|-------|----------|----|----|---------|----------|----|------|
| Q1    | <--- F1  | 1  |    |         | 0.781    | 0.887 | 0.577 |
| Q2    | <--- F1  | 1.076 | 0.109 | 9.869 | *** | 0.908 |
| Q3    | <--- F1  | 1  | 0.12 | 8.309 | *** | 0.79  |
| Q4    | <--- F1  | 1.088 | 0.118 | 9.243 | *** | 0.86  |
| Q5    | <--- F1  | 0.575 | 0.131 | 4.392 | *** | 0.452 |
| Q6    | <--- F1  | 0.806 | 0.117 | 6.904 | *** | 0.678 |
| Q7    | <--- F2  | 1  |    |         | 0.779    | 0.803 | 0.461 |
| Q8    | <--- F2  | 0.781 | 0.126 | 6.216 | *** | 0.669 |
| Q9    | <--- F2  | 0.91  | 0.123 | 7.42  | *** | 0.819 |
| Q10   | <--- F2  | 0.494 | 0.13  | 3.791 | *** | 0.416 |
| Q11   | <--- F2  | 0.78  | 0.132 | 5.921 | *** | 0.639 |
| Q12   | <--- F3  | 1  |    |         | 0.371    | 0.632 | 0.390 |
| Q13   | <--- F3  | 0.973 | 0.329 | 2.953 | 0.003 | 0.542 |
| Q14   | <--- F3  | 1.891 | 0.598 | 3.164 | 0.002 | 0.86  |
| Q15   | <--- F4  | 1  |    |         | 0.727    | 0.747 | 0.596 |
| Q16   | <--- F4  | 1.308 | 0.378 | 3.463 | *** | 0.815 |

***p<0.001.

AET, adjuvant endocrine therapy; BC, breast cancer; CR, critical ratio; PSA, psychosocial adaptation.

**Table 4**  Discrimination and model fit of confirmatory factor analysis for the questionnaire

| Items            | Emotional response | Self-worth | Physical impacts | Social communication | CMIN/DF | RMSEA | CFI  | PNFI | AIC       |
|------------------|--------------------|------------|------------------|----------------------|---------|-------|------|------|-----------|
| Emotional response | 0.760              |            |                  |                      | 1.366*  | 0.062 | 0.941| 0.667| 209.819   |
| Self-worth       | 0.290              | 0.679      |                  |                      |         |       |      |      |           |
| Physical impacts | 0.655              | 0.478      | 0.625            |                      |         |       |      |      |           |
| Social communication | 0.399             | 0.165      | 0.405            | 0.772                |         |       |      |      |           |

*p<0.05.
Psychometric properties

Internal consistency
The Cronbach’s alpha coefficient of the PSA questionnaire among women with BC treated with AET and the four subscales were 0.876, 0.899, 0.790, 0.664 and 0.730, respectively (table 2). Correlation analysis showed that the correlation coefficients between each dimension and the total questionnaire ranged from 0.573 to 0.857 (p<0.01; table 2).

Test–retest reliability
After 10–18 days, 30 patients answered the questionnaire again, with a correlation coefficient of 0.846 for both measures (p<0.01).

Convergent validity
The correlation coefficient between the PSA questionnaire among women with BC treated with AET and the GSES was 0.565 (p<0.01).

DISCUSSION

According to the adaptive model theory proposed by Roy, an American nursing theorist, individuals determine their ability to cope with various stress stimuli based on self-cognition and emotional state evaluation, so as to adopt adaptive response behaviours.29 Based on Roy’s adaptation theory and emotional state evaluation, so as to adopt adaptive thinking of various stress stimuli based on self-cognition and relevant.32 33

In practice, the four-factor structure can display the connotation of PSA in patients with BC with AET more finely and intuitively. In short, these statistical correlations and structural relationships can be reasonably explained by logical relationships.34 The KMO of the 16 questionnaires was 0.880, which was considered suitable for factor analysis.35 Four subscales were extracted, and the factor load of each item of the questionnaire was >0.60.36

The reliability and validity of the 16-item questionnaire, which can be used as a tool for clinical evaluation and further study, were verified in this study. This will help healthcare providers to evaluate PSA in women with BC and provide an appropriate basis for women with AET to adapt to it and improve their quality of life.

Acknowledgements The authors thank the breast cancer specialists, psychologists and statisticians who were consulted during the development of the questionnaire and all the patients who participated in the study.

Contributors HJ and FJ wrote the article; XZ, YD, HX and FJ designed the research; HJ performed the research; HJ, XZ and YD analysed the data. All authors approved the final version of the article, including the authorship list. FJ is guarantor for the work.
Funding Study on psychosocial factors influencing quality of life in breast cancer patients. This work was supported by the Science and Technology Department of Liaoning Province (2008225010-3).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study involves human participants and was approved by This study was approved by the ethics committee at First Affiliated Hospital of China Medical University (Project No.2016-5-2). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Not applicable.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Haoran Jiang http://orcid.org/0000-0002-4792-6607 Xiujie Zhang http://orcid.org/0000-0002-0873-7977

REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
2. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 2019;37:423–8.
3. Pagani O, Francis PA, Fleming GF, et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from text and soft. J Clin Oncol 2020;38:1293–303.
4. Ruhstaller T, Giobbie-Hurder A, Colleoni M, et al. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the big 1-98 trial. J Clin Oncol 2019;37:105–14.
5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast cancer version 4, 2020. Available: https://www.nccn.org [Accessed 31 May 2020].
6. Hsiao F-H, Kuo W-H, Jow G-Y, et al. The changes of quality of life and their correlations with psychosocial factors following surgery among women with breast cancer from the post-surgery to post-treatment survivorship. Breast 2019;44:59–65.
7. Finck C, Barradas S, Zenger M, et al. Quality of life in breast cancer patients: associations with optimism and social support. Int J Clin Health Psychol 2018;18:27–34.
8. van Vulpen JK, Peeters PHM, Velthuis MJ, et al. Effects of physical exercise during adjuvant breast cancer treatment on physical and psychosocial dimensions of cancer-related fatigue: a meta-analysis. Maturitas 2016;85:104–11.
9. Pitman A, Suleman S, Hyde N, et al. Depression and anxiety in patients with cancer. BMJ 2018:361:k1415.
10. Sebaoun P, Frederic M, Weryha G, et al. [Tolerance of Tamoxifen as an adjuvant therapy and long-term follow up of 55 premenopausal breast cancer patients, cared for at the institut de cancérologie de Lorraine, treated with Tamoxifen]. Bull Cancer 2019;106;S75–100.
11. Kuba S, Ishida M, Nakamura Y, et al. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer. Breast Cancer 2016;23:128–33.
12. Toivonen KI, Williamson TM, Carlsson LE, et al. Potentially modifiable factors associated with adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review. Cancers 2020;13. doi:10.3390/cancers13101017. [Epub ahead of print: 31 12 2020].
13. Choo SB, Saifulbahri A, Zullifki SN, et al. Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia. Cimacancer 2019;22:175–81.
14. Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther 2018:18:1101–12.
15. Stanton AL, Bower JE. Psychological adjustment in breast cancer survivors. Adv Exp Med Biol 2015;862:203–21.
16. Brandao T, Schulz MS, Matos PM. Psychological adjustment after breast cancer: a systematic review of longitudinal studies. Psychooncology 2017;26:917–26.
17. Londoño Y, McMillan DE. Psychosocial adaptation: an evolutionary concept analysis exploring a common multidisciplinary language. J Adv Nurs 2016;71:2504–19.
18. AntonakRF, M. J.Leathy. Case management forrehabilitation health professionals. Osage Beach, MO: Aspen ProfessionalServices. In: Chan F, Saunders J, eds. Psycho-Social aspeccs of chronic illness and disability. 2. 2nd ed. 2005.; 2. 3–43.
19. Chan F, da Silva Cardoso E, Cronister JT, et al. Encyclopedia of behavioral medicine. New York: Springer, 2013.
20. Livneh H, Antonak RF. Case management forrehabilitation health professionals. In: Chan F, Leahy MJ, Saunders J, eds. Psycho-Social aspects of chronic illness and disability. 2. Osage Beach: Aspen ProfessionalServices, 2005.: 2. 3–43.
21. Oszilovszka E, Stai J, Chabowski M, et al. Illness perception and quality of life in patients with breast cancer. Cancers 2022;14. doi:10.3390/cancers14051214. [Epub ahead of print: 25 02 2022].
22. Bakan G, Inci FH. Predictor of self-efficacy in individuals with chronic disease: stress-coping strategies. J Clin Nurs 2021:30:874–81.
23. Derogatis LR. The psychosocial adjustment to illness scale (PAIs). J Psychosom Res 1986;30:77–91.
24. Kolokotroni P, Anagnotopoupolo F, Missitsiz I. Psychosocial adjustment to illness scale: factor structure, reliability, and validity assessment in a sample of Greek breast cancer patients. Women Health 2017;57:705–22.
25. Schwab DP. Book review: research methods for organizational studies. Organ Res Methods 2006;9:572–4.
26. Ezzedine K, Bennani M, Shourick J, et al. A method for designing a patient burden questionnaire in dermatology. Clin Cosmet Investig Dermatol 2020;13:521–8.
27. Charmaz K. Constructing grounded theory. London: Sage, 2006.
28. Mystakidou K, Parpa E, Talika E, et al. General perceived self-efficacy: validation analysis in Greek cancer patients. Support Care Cancer 2008;16:1317–22.
29. Roy C. Extending the Roy adaptation model to meet changing global needs. Nurs Sci Q 2011;24:345–51.
30. Roy C. Pearson Education. In: The Roy adaptation model, upper saddle river NJ, 2009.
31. Batista-Foguet JM, Coenders G, Alonso J, [Confirmatory factor analysis. Its role on the validation of health related questionnaires]. Med Clin 2004;122 Suppl 1:21–7.
32. Quadrelli S, Davoudi M, Galindez F, et al. Reliability of a 25-item low-stakes multiple-choice assessment of bronchoscopic knowledge. Chest 2009;135:315–21.
33. University, NCS. Reliability analysis: key concepts and terms. Available: http://www2.chass.ncsu.edu/garson/pa765/reliabil.htm [Accessed 18 Oct 2008].
34. Williams LS, Weinberger M, Harris LE, et al. Development of a Stroke-Specific quality of life scale. Stroke 1999;30:1362–9.
35. Tang W-K, Mak K-K, Kam PH-M, et al. Reliability and validity of the euthanasia attitude scale (EAS) for Hong Kong medical doctors. Am J Hosp Palliat Care 2010;27:320–4.
36. University, NCS. Validity analysis: key concepts and terms. Available: http://www2.chass.ncsu.edu/garson/pa765/reliab.htm. [Accessed 18 Oct 2008].
37. Grafton KV, Foster NE, Wright CC. Test-Retest reliability of the short-form McGill pain questionnaire: assessment of intraclass correlation coefficients and limits of agreement in patients with osteoarthritis. Clin J Pain 2005;21:73–82.
38. X-W, Zhao T, Chang X-qin, [Assessment on the reliability and validity of the Dermatology Life Quality Index in Chinese version]. Zhonghua Liu Xing Bing Xue Za Zhi 2004;25:791–3.
39 Qiu H. Quantitative research and statistical analysis. In: . 4.
Chongqing: Chongqing university press, 2013.

40 Burgess C, Cornelius V, Love S, et al. Depression and anxiety in
women with early breast cancer: five year observational cohort study. 
BMJ 2005;330:702.

41 Cronbach LJ, Warrington WG. Time-limit tests: estimating 
their reliability and degree of speeding. Psychometrika
1951;16:167–88.

42 Heo M, Kim N, Faith MS. Statistical power as a function of Cronbach 
alpha of instrument questionnaire items. BMC Med Res Methodol
2015;15:86.

43 Wild D, Grove A, Martin M, et al. Principles of good practice for 
the translation and cultural adaptation process for patient-reported 
outcomes (pro) measures: report of the ISPOR Task force for 
translation and cultural adaptation. Value Health 2005;8:94–104.